PA
TEVA icon

Prism Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Prism Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,345
Closed -$100K – 55
2020
Q4 		$100K Hold
10,345
– – 0.04% 52
2020
Q3 		$93K Hold
10,345
– – 0.04% 46
2020
Q2 		$128K Sell
10,345
-300,008
-97% -$3.39M 0.06% 45
2020
Q1 		$2.79M Buy
310,353
+7,396
+2% +$75.8K 1.8% 15
2019
Q4 		$2.97M Buy
302,957
+28,583
+10% +$255K 1.5% 14
2019
Q3 		$1.89M Buy
274,374
+83,822
+44% +$642K 1.06% 29
2019
Q2 		$1.76M Buy
190,552
+60,372
+46% +$728K 1% 29
2019
Q1 		$2.04M Buy
130,180
+15,072
+13% +$266K 1.17% 26
2018
Q4 		$1.77M Sell
115,108
-2,291
-2% -$47K 1.13% 25
2018
Q3 		$2.49M Sell
117,399
-14,752
-11% -$342K 1.45% 19
2018
Q2 		$3.19M Sell
132,151
-5,564
-4% -$113K 1.7% 11
2018
Q1 		$2.65M Sell
137,715
-38,796
-22% -$757K 1.49% 11
2017
Q4 		$3.35M Buy
+176,511
New +$2.66M 1.84% 7

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Prism Advisors's TEVA Position: Q1 2021 in Review

Prism Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2021, closing a stake of 10,345 shares — an estimated $100K sold.

Prism Advisors first reported a position in TEVA in Q4 2017 and held it in 13 quarters. The position peaked at $3.35M in Q4 2017. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

  • Prism Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Prism Advisors sold 10,345 Teva Pharmaceuticals shares in Q1 2021, an estimated $100K.
  • Prism Advisors first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 13 quarters.
  • Prism Advisors's Teva Pharmaceuticals position peaked at $3.35M in Q4 2017.
  • 451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2021.

Based on Prism Advisors's 13F filing for Q1 2021, filed 15 Apr 2021.